{
    "id": "dbpedia_745_2",
    "rank": 62,
    "data": {
        "url": "https://dumas.ccsd.cnrs.fr/dumas-00982939v1/html_references",
        "read_more_link": "",
        "language": "en",
        "title": "",
        "top_image": "",
        "meta_img": "",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": null,
        "text": ". Anatomie-du-pancréas, Service de chirurgie générale et digestive Hôpital Saint-Antoine. [cited 2014 Feb 24] Available from: http://chirurgie-digestive-sat\n\nS. Wack and . Marc, Etude de modalités multithérapeutiques et diagnostiques appliquées au cancer du pancréas, Thèse de doctorat : Aspects moléculaires et cellulaires de la biologie\n\nC. Médecine, Ostéopathie -Physiologie --Partie 5 : Le pancréas [Internet]\n\nB. Laverdet, Physiopathologie du pancréas : Rôle de l'inflammation dans la cancérogenèse du pancréas exocrine\n\nA. Serge and S. Thayer, Available from: http://www.med.univ- rennes1.fr/cerf Therapeutic targeting of pancreatic stroma, Pancreatic Cancer and Tumor Microenvironment [Internet]. Trivandrum (India): Transworld Research Network\n\nR. Kadaba, H. Birke, J. Wang, S. Hooper, C. Andl et al., Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes, The Journal of Pathology, vol.487, issue.3, pp.107-124\n\nDOI : 10.1002/path.4172\n\nJ. Kleeff, P. Beckhove, I. Esposito, S. Herzig, P. Huber et al., Pancreatic cancer microenvironment, International Journal of Cancer, vol.3, issue.4, pp.699-705\n\nDOI : 10.1002/ijc.22871\n\nA. Hezel, A. Kimmelman, B. Stanger, N. Bardeesy, and R. Depinho, Genetics and biology of pancreatic ductal adenocarcinoma, Genes & Development, vol.20, issue.10, pp.1218-1267\n\nDOI : 10.1101/gad.1415606\n\nD. Magliano, M. Logsdon, and C. , Roles for KRAS in Pancreatic Tumor Development and Progression, Gastroenterology, vol.144, issue.6, pp.1220-1229\n\nDOI : 10.1053/j.gastro.2013.01.071\n\nT. Hackert and M. Büchler, Pancreatic Cancer: Advances in Treatment, Results and Limitations, Digestive Diseases, vol.31, issue.1, pp.51-57\n\nDOI : 10.1159/000347178\n\nP. Michl and T. Gress, Current concepts and novel targets in advanced pancreatic cancer, Gut, vol.62, issue.2, pp.317-343\n\nDOI : 10.1136/gutjnl-2012-303588\n\nD. Céphalique, Service de chirurgie générale et digestive Hôpital Saint-Antoine\n\nD. Al, Duodénopancréatectomie céphalique : indications, résultats et prise en charge des complications, Chirurgie, vol.163, issue.25, pp.1563-1569\n\nA. Sauvanet, Conséquences fonctionnelles de la chirurgie pancréatique. Hépato-Gastro, Nov, vol.229, issue.6, pp.417-443\n\nP. Totale, Service de chirurgie générale et digestive Hôpital Saint-Antoine Available from: http://chirurgie-digestive-sat.aphp.fr/chirurgie/pancreatectomies/pancreatectomie-totale/ 21, AM. Therapeutic advances in pancreatic cancer. Gastroenterology, pp.1316-1342\n\nC. Moertel, S. Frytak, R. Hahn, O. Connell, M. Reitemeier et al., Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group, Cancer, vol.47, issue.8, pp.1705-1715\n\nDOI : 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4\n\nJ. Neoptolemos, D. Stocken, H. Friess, C. Bassi, J. Dunn et al., A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer, New England Journal of Medicine, vol.350, issue.12, pp.1200-1210\n\nDOI : 10.1056/NEJMoa032295\n\nN. Merchant, J. Rymer, E. Koehler, G. Ayers, J. Castellanos et al., Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg, pp.829-838\n\nB. Chauffert, F. Mornex, F. Bonnetain, P. Rougier, C. Mariette et al., Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study, Annals of Oncology, vol.19, issue.9, pp.1592-1601\n\nDOI : 10.1093/annonc/mdn281\n\nURL : https://hal.archives-ouvertes.fr/hal-00363727\n\nS. Gillen, T. Schuster, M. Z. Büschenfelde, C. Friess, H. Kleeff et al., Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages, PLoS Medicine, vol.23, issue.4\n\nDOI : 10.1371/journal.pmed.1000267.s005\n\nA. Andriulli, V. Festa, E. Botteri, M. Valvano, M. Koch et al., Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies, Annals of Surgical Oncology, vol.13, issue.5, pp.1644-62\n\nDOI : 10.1245/s10434-011-2110-8\n\nM. Assifi, X. Lu, G. Eibl, H. Reber, G. Li et al., Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials, Surgery, vol.150, issue.3, pp.466-73\n\nDOI : 10.1016/j.surg.2011.07.006\n\nJ. Klinkenbijl, J. Jeekel, T. Sahmoud, R. Van-pel, M. Couvreur et al., Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary Region, Annals of Surgery, vol.230, issue.6, pp.776-782\n\nDOI : 10.1097/00000658-199912000-00006\n\nF. Giuliani, D. Maio, M. Colucci, G. Perrone, and F. , Conventional Chemotherapy of Advanced Pancreatic Cancer, Current Drug Targets, vol.13, issue.6, pp.795-801\n\nDOI : 10.2174/138945012800564149\n\nV. Hoff, D. Ramanathan, R. Borad, M. Laheru, D. Smith et al., -Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial, Journal of Clinical Oncology, vol.29, issue.34, pp.4548-54\n\nDOI : 10.1200/JCO.2011.36.5742\n\nURL : https://hal.archives-ouvertes.fr/hal-00261277\n\nT. Conroy, C. Gavoille, E. Samalin, M. Ychou, and M. Ducreux, The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer, Current Oncology Reports, vol.23, issue.Suppl 9, pp.182-191\n\nDOI : 10.1007/s11912-012-0290-4\n\nS. Gourgou-bourgade, C. Bascoul-mollevi, F. Desseigne, M. Ychou, O. Bouché et al., Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial, Journal of Clinical Oncology, vol.31, issue.1, pp.23-32\n\nDOI : 10.1200/JCO.2012.44.4869\n\nR. Gillies, D. Verduzco, and R. Gatenby, Evolutionary dynamics of carcinogenesis and why targeted therapy does not work, Nature Reviews Cancer, vol.196, issue.7, pp.487-93\n\nDOI : 10.1038/nrc3298\n\nE. Rowinsky, J. Windle, V. Hoff, and D. , Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development, Journal of Clinical Oncology, vol.17, issue.11, pp.3631-52\n\nDOI : 10.1200/JCO.1999.17.11.3631\n\nC. Raut, S. Nawrocki, L. Lashinger, D. Davis, S. Khanbolooki et al., Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts, Cancer Biology & Therapy, vol.3, issue.12, pp.1217-1241\n\nDOI : 10.4161/cbt.3.12.1221\n\nL. Martin, X. Li, B. Kleiber, E. Ellison, M. Bloomston et al., VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA, Annals of Oncology, vol.23, issue.11, pp.2812-2832\n\nDOI : 10.1093/annonc/mds134\n\nM. Erkan, Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis, The Journal of Pathology, vol.35, issue.suppl???2, pp.4-7\n\nDOI : 10.1002/path.4213\n\nH. Miyamoto, T. Murakami, K. Tsuchida, H. Sugino, H. Miyake et al., Tumor-Stroma Interaction of Human Pancreatic Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins, Pancreas, vol.28, issue.1, pp.38-44\n\nDOI : 10.1097/00006676-200401000-00006\n\nD. Mahadevan, V. Hoff, and D. , Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther\n\nC. Whatcott, H. Han, R. Posner, V. Hoff, and D. , Tumor-Stromal Interactions in Pancreatic Cancer, Critical Reviews?? in Oncogenesis, vol.18, issue.1 - 2, pp.135-51\n\nDOI : 10.1615/CritRevOncog.v18.i1-2.80\n\nM. Erkan, C. Reiser-erkan, C. Michalski, B. Kong, I. Esposito et al., The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance, Current Molecular Medicine, vol.12, issue.3, pp.288-303\n\nDOI : 10.2174/156652412799218921\n\nM. Korc, Pancreatic cancer???associated stroma production, The American Journal of Surgery, vol.194, issue.4, pp.84-86\n\nDOI : 10.1016/j.amjsurg.2007.05.004\n\nURL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2094116\n\nA. Neesse, P. Michl, K. Frese, C. Feig, N. Cook et al., Stromal biology and therapy in pancreatic cancer, Gut, vol.60, issue.6, pp.861-869\n\nDOI : 10.1136/gut.2010.226092\n\nM. Hidalgo and A. Maitra, The Hedgehog Pathway and Pancreatic Cancer, New England Journal of Medicine, vol.361, issue.21, pp.2094-2100\n\nDOI : 10.1056/NEJMcibr0905857\n\nR. Kalluri and M. Zeisberg, Fibroblasts in cancer, Nature Reviews Cancer, vol.59, issue.5, pp.392-401\n\nDOI : 10.1038/nrc1877\n\nM. Apte, J. Wilson, A. Lugea, and S. Pandol, A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment, Gastroenterology, vol.144, issue.6, pp.1210-1219\n\nDOI : 10.1053/j.gastro.2012.11.037\n\nP. Provenzano, C. Cuevas, A. Chang, V. Goel, V. Hoff et al., Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell, pp.418-447\n\nX. Li, Q. Ma, Q. Xu, W. Duan, J. Lei et al., Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment, Current Pharmaceutical Design, vol.18, issue.17, pp.2404-2419\n\nDOI : 10.2174/13816128112092404\n\nR. Hwang, T. Moore, T. Arumugam, V. Ramachandran, K. Amos et al., Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res, Feb, vol.168, issue.3, pp.918-944\n\nA. Ene-obong, A. Clear, J. Watt, J. Wang, R. Fatah et al., Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma, Gastroenterology, vol.145, issue.5, pp.1121-1153\n\nDOI : 10.1053/j.gastro.2013.07.025\n\nT. Mace, Z. Ameen, A. Collins, S. Wojcik, M. Mair et al., Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res, pp.3007-3025\n\nW. Schneiderhan, F. Diaz, M. Fundel, S. Zhou, M. Siech et al., Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay, Journal of Cell Science, vol.120, issue.3, pp.512-521\n\nDOI : 10.1242/jcs.03347\n\nT. Armstrong, G. Packham, L. Murphy, A. Bateman, J. Conti et al., Type I Collagen Promotes the Malignant Phenotype of Pancreatic Ductal Adenocarcinoma, Clinical Cancer Research, vol.10, issue.21, pp.7427-7464\n\nDOI : 10.1158/1078-0432.CCR-03-0825\n\nS. Dangi-garimella, V. Sahai, K. Ebine, K. Kumar, and H. Munshi, Three-Dimensional Collagen I Promotes Gemcitabine Resistance In Vitro in Pancreatic Cancer Cells through HMGA2-Dependent Histone Acetyltransferase Expression, PLoS ONE, vol.30, issue.5, p.64566\n\nDOI : 10.1371/journal.pone.0064566.s001\n\nJ. Grzesiak and M. Bouvet, The ??2??1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines, British Journal of Cancer, vol.52, issue.9, pp.1311-1320\n\nDOI : 10.1083/jcb.121.5.1141\n\nY. Shintani, M. Hollingsworth, M. Wheelock, and K. Johnson, Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res, pp.11745-53\n\nY. Imamichi, A. König, T. Gress, and A. Menke, Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer, Oncogene, vol.92, issue.16, pp.2381-2386\n\nDOI : 10.1038/sj.onc.1210012\n\nW. Huanwen, L. Zhiyong, S. Xiaohua, R. Xinyu, K. W. Tonghua et al., Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines, Molecular Cancer, vol.8, issue.1, p.125\n\nDOI : 10.1186/1476-4598-8-125\n\nJ. Grzesiak, K. Smith, D. Burton, L. Deftos, and M. Bouvet, Integrin-mediated laminin-1 adhesion upregulates CXCR4 and IL-8 expression in pancreatic cancer cells. Surgery, pp.804-818\n\nP. Michl and T. Gress, Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid, Gut, vol.61, issue.10, pp.1377-1386\n\nDOI : 10.1136/gutjnl-2012-302604\n\nY. Zhi, M. Song, P. Wang, and T. Zhang, Suppression of matrix metalloproteinase-2 ??via RNA interference inhibits pancreatic carcinoma cell invasiveness and adhesion, World Journal of Gastroenterology, vol.15, issue.9, pp.1072-1080\n\nDOI : 10.3748/wjg.15.1072\n\nV. Bister, T. Skoog, S. Virolainen, T. Kiviluoto, P. Puolakkainen et al., Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma, Modern Pathology, vol.37, issue.11, pp.1128-1168\n\nDOI : 10.1038/modpathol.3800956\n\nQ. Ben, J. X. Liu, J. Cai, X. Yuan, F. Yuan et al., Periostin, a matrix specific protein, is associated with proliferation and invasion of pancreatic cancer, Oncol Rep, vol.25, issue.3, pp.709-725\n\nA. Juuti, S. Nordling, J. Louhimo, J. Lundin, and C. Haglund, Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation, Journal of Clinical Pathology, vol.57, issue.11, pp.1151-1156\n\nDOI : 10.1136/jcp.2003.015818\n\nJ. Chen, Z. Chen, M. Chen, D. Li, Z. Li et al., Role of fibrillar Tenascin-C in metastatic pancreatic cancer, Int J Oncol, vol.34, issue.4, pp.1029-1065\n\nS. Skandalis, D. Kletsas, D. Kyriakopoulou, M. Stavropoulos, and D. Theocharis, The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer, Biochimica et Biophysica Acta (BBA) - General Subjects, vol.1760, issue.8, pp.1217-1242\n\nDOI : 10.1016/j.bbagen.2006.03.021\n\nT. Wight, Versican: a versatile extracellular matrix proteoglycan in cell biology, Current Opinion in Cell Biology, vol.14, issue.5\n\nDOI : 10.1016/S0955-0674(02)00375-7\n\nB. Farrow, D. Berger, and D. Rowley, Tumor-Derived Pancreatic Stellate Cells Promote Pancreatic Cancer Cell Invasion Through Release of Thrombospondin-2, Journal of Surgical Research, vol.156, issue.1, pp.155-60\n\nDOI : 10.1016/j.jss.2009.03.040\n\nD. Albo, D. Berger, J. Vogel, and G. Tuszynski, Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer, Journal of Gastrointestinal Surgery, vol.3, issue.4\n\nDOI : 10.1016/S1091-255X(99)80058-4\n\nJ. Jankun and E. Skrzypczak-jankun, Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride, Cancer Biochem Biophys, vol.17, issue.12, pp.109-132\n\nS. Lunardi, R. Muschel, and T. Brunner, The stromal compartments in pancreatic cancer: Are there any therapeutic targets?, Cancer Letters, vol.343, issue.2, pp.147-55\n\nDOI : 10.1016/j.canlet.2013.09.039\n\nL. Coussens and Z. Werb, Inflammation and cancer, Nature, vol.2, issue.6917, pp.860-867\n\nDOI : 10.1006/cyto.1996.0074\n\nA. Mantovani, P. Allavena, A. Sica, and F. Balkwill, Cancer-related inflammation, Nature, vol.342, issue.7203, pp.436-480\n\nDOI : 10.1038/nature07205\n\nB. Farrow and B. Evers, Inflammation and the development of pancreatic cancer, Surgical Oncology, vol.10, issue.4, pp.153-69\n\nDOI : 10.1016/S0960-7404(02)00015-4\n\nK. Sideras, H. Braat, J. Kwekkeboom, C. Van-eijck, M. Peppelenbosch et al., Review: Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies Impact of tumour associated macrophages in pancreatic cancer, Cancer Treat Rev Nov Bmb Reports, vol.2346, issue.773, pp.131-139\n\nM. Porembka, J. Mitchem, B. Belt, C. Hsieh, H. Lee et al., Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth, Cancer Immunology, Immunotherapy, vol.181, issue.8, pp.1373-85\n\nDOI : 10.1007/s00262-011-1178-0\n\nA. Bazhin, I. Shevchenko, V. Umansky, J. Werner, and S. Karakhanova, Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy, Cancer Immunology, Immunotherapy, vol.15, issue.23, pp.59-65\n\nDOI : 10.1007/s00262-013-1485-8\n\nU. Liyanage, T. Moore, H. Joo, Y. Tanaka, V. Herrmann et al., Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma, The Journal of Immunology, vol.169, issue.5, pp.2756-61\n\nDOI : 10.4049/jimmunol.169.5.2756\n\nG. Garcea, H. Doucas, W. Steward, A. Dennison, and D. Berry, HYPOXIA AND ANGIOGENESIS IN PANCREATIC CANCER, ANZ Journal of Surgery, vol.5, issue.11, pp.830-872\n\nDOI : 10.1038/nm0295-149\n\nJ. Van-der-zee, C. Van-eijck, W. Hop, H. Van-dekken, B. Dicheva et al., Angiogenesis: A prognostic determinant in pancreatic cancer?, European Journal of Cancer, vol.47, issue.17, pp.2576-84\n\nDOI : 10.1016/j.ejca.2011.08.016\n\nK. Olive, M. Jacobetz, C. Davidson, A. Gopinathan, D. Mcintyre et al., Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, pp.1457-61\n\nM. Sunamura, D. Duda, M. Ghattas, L. Lozonschi, F. Motoi et al., Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer, Angiogenesis, vol.6, issue.1, pp.15-24\n\nDOI : 10.1023/A:1025803600840\n\nN. Beasley, C. Wykoff, P. Watson, R. Leek, H. Turley et al., Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density, Cancer Res, issue.13, pp.615262-615269\n\nT. Sakurai, M. Kudo, N. Fukuta, T. Nakatani, M. Kimura et al., Involvement of Angiotensin II and Reactive Oxygen Species in Pancreatic Fibrosis, Pancreatology, vol.11, issue.2, pp.7-13\n\nDOI : 10.1159/000323478\n\nY. Nakai, H. Isayama, H. Ijichi, T. Sasaki, N. Sasahira et al., Inhibition of renin???angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine, British Journal of Cancer, vol.23, issue.11, pp.1644-1652\n\nDOI : 10.1016/j.jhep.2009.04.011\n\nA. Masamune, S. Hamada, K. Kikuta, T. Takikawa, S. Miura et al., The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice, Scandinavian Journal of Gastroenterology, vol.580, issue.5, pp.602-611\n\nDOI : 10.1038/sj.bjc.6605955\n\nV. Chauhan, J. Martin, H. Liu, D. Lacorre, S. Jain et al., Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels, Nature Communications, vol.22, p.2516\n\nDOI : 10.1038/nmeth.1475\n\nURL : http://doi.org/10.1038/ncomms3516\n\nJ. Guan, H. Zhang, Z. Wen, Y. Gu, Y. Cheng et al., Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells, Cancer Letters, vol.345, issue.1, pp.132-141\n\nDOI : 10.1016/j.canlet.2013.12.006\n\nR. Maréchal, P. Demetter, N. Nagy, A. Berton, C. Decaestecker et al., High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma, British Journal of Cancer, vol.66, issue.9, pp.1444-51\n\nDOI : 10.1038/sj.bjc.6605020\n\nS. Singh, S. Srivastava, A. Bhardwaj, L. Owen, and A. Singh, CXCL12???CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy, British Journal of Cancer, vol.19, issue.11, pp.1671-1680\n\nDOI : 10.1016/j.jss.2006.06.031\n\nC. Feig, A. Gopinathan, A. Neesse, D. Chan, N. Cook et al., The Pancreas Cancer Microenvironment, Clinical Cancer Research, vol.18, issue.16, pp.4266-76\n\nDOI : 10.1158/1078-0432.CCR-11-3114\n\nS. Wrzesinski, Y. Wan, and R. Flavell, Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res Off J Am Assoc Cancer Res, pp.5262-70\n\nN. Bhola, J. Balko, T. Dugger, M. Kuba, V. Sánchez et al., TGF-?? inhibition enhances chemotherapy action against triple-negative breast cancer, Journal of Clinical Investigation, vol.123, issue.3, pp.1348-58\n\nDOI : 10.1172/JCI65416DS1\n\nURL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582135\n\nS. Hingorani, L. Wang, A. Multani, C. Combs, T. Deramaudt et al., Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, pp.469-83\n\nB. Singh, J. Fu, R. Srivastava, and S. Shankar, Hedgehog Signaling Antagonist GDC-0449 (Vismodegib) Inhibits Pancreatic Cancer Stem Cell Characteristics: Molecular Mechanisms, PLoS ONE, vol.6, issue.11, p.27306\n\nDOI : 10.1371/journal.pone.0027306.g007\n\nURL : http://doi.org/10.1371/journal.pone.0027306\n\nR. Hwang, T. Moore, M. Hattersley, M. Scarpitti, Y. B. Devereaux et al., Inhibition of the Hedgehog Pathway Targets the Tumor-Associated Stroma in Pancreatic Cancer, Molecular Cancer Research, vol.10, issue.9, pp.1147-57\n\nDOI : 10.1158/1541-7786.MCR-12-0022\n\nM. Jacobetz, D. Chan, A. Neesse, T. Bapiro, N. Cook et al., Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer, Gut, vol.62, issue.1, pp.112-132\n\nDOI : 10.1136/gutjnl-2012-302529\n\nJ. Stokes, S. Adair, J. Slack-davis, D. Walters, R. Tilghman et al., Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment, Molecular Cancer Therapeutics, vol.10, issue.11, pp.2135-2180\n\nDOI : 10.1158/1535-7163.MCT-11-0261\n\nD. Yardley, nab-Paclitaxel mechanisms of action and delivery, Journal of Controlled Release, vol.170, issue.3, pp.365-72\n\nDOI : 10.1016/j.jconrel.2013.05.041\n\nR. Alvarez, M. Musteanu, E. Garcia-garcia, P. Lopez-casas, D. Megias et al., Stromal disrupting effects of nab-paclitaxel in pancreatic cancer, British Journal of Cancer, vol.29, issue.4, pp.926-959\n\nDOI : 10.1038/bjc.2013.415\n\nK. Frese, A. Neesse, N. Cook, T. Bapiro, M. Lolkema et al., nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov, pp.260-269\n\nM. Hartel, D. Mola, F. Gardini, A. Zimmermann, A. et al., Desmoplastic Reaction Influences Pancreatic Cancer Growth Behavior, World Journal of Surgery, vol.255, issue.8, pp.818-843\n\nDOI : 10.1007/s00268-004-7147-4\n\nA. Neesse, K. Frese, T. Bapiro, T. Nakagawa, M. Sternlicht et al., CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer, Proceedings of the National Academy of Sciences, vol.110, issue.30, pp.12325-12355\n\nDOI : 10.1073/pnas.1300415110\n\nH. Ijichi, A. Chytil, A. Gorska, M. Aakre, B. Bierie et al., Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma, Journal of Clinical Investigation, vol.121, issue.10, pp.4106-4123\n\nDOI : 10.1172/JCI42754DS1\n\nS. Wang, Y. Wu, Y. Hou, X. Guan, M. Castelvetere et al., CXCR2 Macromolecular Complex in Pancreatic Cancer: A Potential Therapeutic Target in Tumor Growth, Translational Oncology, vol.6, issue.2, pp.216-241\n\nDOI : 10.1593/tlo.13133\n\nG. Beatty, E. Chiorean, M. Fishman, B. Saboury, U. Teitelbaum et al., CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science, pp.1612-1618\n\nJ. Nemunaitis, Vaccines in cancer: GVAX??, a GM-CSF gene vaccine, Expert Review of Vaccines, vol.4, issue.3, pp.259-74\n\nDOI : 10.1586/14760584.4.3.259\n\nD. Le, E. Lutz, J. Uram, E. Sugar, B. Onners et al., Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer, Journal of Immunotherapy, vol.36, issue.7, pp.382-391\n\nDOI : 10.1097/CJI.0b013e31829fb7a2\n\nF. Gansauge, B. Poch, R. Kleef, and M. Schwarz, Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>??</sup>) in the Palliative Treatment of Pancreatic Cancer, Current Medicinal Chemistry, vol.20, issue.38, pp.4827-4862\n\nDOI : 10.2174/09298673113206660290\n\nT. Ghansah, N. Vohra, K. Kinney, A. Weber, K. Kodumudi et al., Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma, Cancer Immunology, Immunotherapy, vol.82, issue.6, pp.1083-91\n\nDOI : 10.1007/s00262-013-1407-9\n\nH. Kameshima, T. Tsuruma, G. Kutomi, H. Shima, Y. Iwayama et al., Immunotherapeutic benefit of ?interferon (IFN?) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients, Cancer Sci\n\nC. Steding, S. Wu, Y. Zhang, M. Jeng, B. Elzey et al., The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis, Immunology, vol.70, issue.2 Pt 2, pp.221-259\n\nDOI : 10.1111/j.1365-2567.2011.03429.x\n\nK. Wagner, P. Schulz, A. Scholz, B. Wiedenmann, and A. Menrad, The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer, Clinical Cancer Research, vol.14, issue.15, pp.4951-60\n\nDOI : 10.1158/1078-0432.CCR-08-0157\n\nD. Walters, J. Lindberg, S. Adair, T. Newhook, C. Cowan et al., Inhibition of the growth of patientderived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib, pp.143-55\n\nJ. Valentino, J. Li, Y. Zaytseva, W. Mustain, V. Elliott et al., Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors, Clinical Cancer Research, vol.20, issue.5, pp.1212-1234\n\nDOI : 10.1158/1078-0432.CCR-13-1897\n\nE. Liu, P. Marincola, and K. Oberg, Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations. Ther Adv Gastroenterol, pp.412-421"
    }
}